Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fungus – except allergen – or component thereof or substance...
Reexamination Certificate
2005-08-02
2005-08-02
Smith, Lynette R. F. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fungus, except allergen, or component thereof or substance...
C435S006120, C435S091200, C536S024300, C536S024310, C536S024320, C536S024330
Reexamination Certificate
active
06923973
ABSTRACT:
Disclosed are peptide and DNA compositions surprisingly found to be effective in generating immune responses against the pathogenic fungiCoccidioidesspp., the causative agents of coccidioidomycosis and Valley Fever. The invention thus provides peptides and DNA constructs, combinations and related biological compositions, and prophylactic and therapeutic methods of using such components to generate effective immune responses againstCoccidioidesspp., includingC. immitis.
REFERENCES:
patent: 5284747 (1994-02-01), Milliman
patent: 5622827 (1997-04-01), McAllister et al.
patent: 5837734 (1998-11-01), Bartsch et al.
patent: 2003/0219455 (2003-11-01), Cole et al.
patent: 2003/0224013 (2003-12-01), Cole et al.
patent: 2004/0001843 (2004-01-01), Galgiani et al.
patent: 2004/0181046 (2004-09-01), Cole et al.
Rudinger et al, in “Peptide Hormones”, edited by Parsons, J.A., University Park Press, Jun. 1976, p. 6.
Burgess et al., The Journal of Cell Biology, 111:2129-2138, 1990).
Burgess et al., The Journal of C ll Biology, 111:2129-2138, 1990).
Jobling et al. ( Mol. Microbiol. 1991, 5(7): 1755-67.
Accession No.: U39835.
Accession No.: U32518.
Cox and Magee, “Coccidioidomycosis: Host Response and Vaccine Development,”Clin. Microbiol. Rev., 17(4):804-839, 2004.
Abuodeh et al., “Resistance toCoccidioides immitisin Mice after Immunization with Recombinant Protein or a DNA Vaccine of a Proline-Rich Antigen,”Infect. Immun., 67(6):2935-2940, 1999.
Ampel, et al., “In Vitro Assessment of Cellular Immunity in Human Coccidioidomycosis: Relationship Between Dermal Hypersensitivity, Lymphocyte Transformation, and Lymphokine Production by Peripheral Blood Mononuclear Cells from Healthy Adults,”J. Infect. Dis., 165:710-715, 1992.
Corry et al., “Cytokine Production by Peripheral Blood Mononuclear Cells in Human Coccidioidomycosis,”J. Infect. Dis., 174:440-443, 1996.
Cox and Magee, “Vaccine Efficacy ofCoccidiodies immitisAntigen 2, ” Progress Report submitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting, Report for Period Jul. 1, 2000-Dec. 31, 2000, Meeting held Dec. 4-5, 2000.
Cox and Magee, “Vaccine Efficacy ofCoccidioides immitisAntigen 2,” Progress Report submitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting Report Period Jan. 1, 1980-Dec. 31, 1999. Meeting held Feb. 22-23, 2000.
Cox and Magee, “Vaccine Efficacy ofCoccidioides immitisAntigen 2,” Progress Report sumbitted to California State Bakersfield Foundation, Valley Fever Vaccine Project Meeting, Report for Period Jan. 1, 2000-Jun. 31, 2000. Meeting held Jun. 13-14, 2000.
Cox and Magee; U.S. Appl. No. 60/178,571; Entitled “Use of DNA and Expressed Protein as a Vaccine Against Coccidiodidomycosis”; by Rebecca A. Cox and D. Mitchell Magee; filed Jan. 28, 2000.
Cox and Magee, “Protective Immunity in Coccidioidomycosis,”Res. Immunology, 149:417-428, 1998.
Dugger et al., “Cloning and Sequence Analysis of the cDNA for a Protein fromCoccidioides immitiswith Immunogenic Potential,”Biochem. Biophys. Res. Comm., 218:485-489, 1996.
Franco et al., “An Immunodominant Cytotoxic T Cell Epitope on the VP7 Rotavirus Protein Overlaps the H2 Signal Peptide,”J. Gen. Viro., 74:2579-2586, 1993.
Hombach et al., “Strictly Transporter of Antigen Presentation (TAP)-Dependent Presentation of an Immunodominant Cytotoxic T Lymphocyte Epitope in the Signal Sequence of a Virus Protein,”J. Exp. Med., 182:1619, 1995.
Jiang et al., “Genetic Vaccination AgainstCoccidioides immitis: Comparison of Vaccine Efficacy of Recombinant Antigen 2 and Antigen 2 cDNA,”Infect. Immun., 67(2):630-635, 1999.
Kirkland et al., “Evaluation of the Proline-Rich Antigen ofCoccidioides immitisas a Vaccine Candidate in Mice,”Infect. Immun., 66(8):3519-3522, 1998.
Kondo et al., “A Single Retroviral Gag Precursor Signal Peptide Recognized by FBL-3 Tumor-Specific Cytotoxic T. Lymphocytes,”J. Virol., 69(11):6735-6741, 1995.
Pan and Cole, “Molecular and Biochemical Characterization of aCoccidioides immitis—Specific Antigen,”Infect. Immun, 63(10):3994-4002, 1995.
Stevens, “Current Concepts: Coccidioidomycosis,”N. Eng. J. Med., 332:1077-1082, 1995.
Zhu et al., “Identification of aCoccidioides immitisAntigen 2 Domain That Expresses B-Cell Reactive Epitopes,”Infect. Immun., 65(8):3376-3380, 1997.
Zhu et al., “Coccidioides immitisAntigen 2: Analysis of Gene and Protein,”Gene, 181:121-125, 1996.
Zhu et al., Molecular Cloning and Characterization ofCoccidioides immitisAntigen 2cDNA,Infect. Immun., 64(7):2695-2699, 1996.
U.S. Appl. No. 10/417,923; Entitled: “Peptides and DNA Encoding the Peptides Useful for Immunizations AgainstCoccidioidesSPP. Infections,” by John N. Galgiani, Kris Orsborn, Tao Peng and Lisa Shubitz; filed Apr. 16, 2003, claiming priority to U.S. Appl. No. 60/373,635, filed Apr. 19, 2002.
Cox Rebecca A.
Jiang Chengyong
Magee D. Mitchell
Baskar Padma
Board of Regents , The University of Texas System
Myers Bigel Sibley & Sajovec P.A.
Smith Lynette R. F.
LandOfFree
Peptide and DNA immunization against Coccidioides immitis... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Peptide and DNA immunization against Coccidioides immitis..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide and DNA immunization against Coccidioides immitis... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3466847